Interim Results of a Phase II Study of Ibrutinib in Relapsed or Refractory MCL


Interim Results of a Phase II Study of Ibrutinib in Relapsed or Refractory MCL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Brad S Kahl, MD (1/17/13)

Wang M et al. Interim results of an international, multicenter, Phase 2 study of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): Durable efficacy and tolerability with longer follow-up. Proc ASH 2012;Abstract 904.

Dr Kahl is Skoronski Chair of Lymphoma Research, Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.